title: Ethics in nanomedicine.
abstract: As the science and technology of nanomedicine speed ahead, ethics, policy and the law are struggling to keep up. It is important to proactively address the ethical, social and regulatory aspects of nanomedicine in order to minimize its adverse impacts on the environment and public health and also to avoid a public backlash. At present, the most significant concerns involve risk assessment, risk management of engineered nanomaterials and risk communication. Although in vivo animal experiments and ex vivo laboratory analyses can increase our understanding of the interaction of engineered nanomaterials in biological systems, they cannot eliminate all of the uncertainty surrounding the exposure of a human subject to nanomedicine products in clinical trials. Significant risks can still materialize after a product has cleared the Phase I hurdle and is in Phase II or III clinical trials. Furthermore, as the use of engineered nanomaterials in nanomedicine increases, questions of social justice, access to healthcare and the use of nanotechnology for physical enhancement become increasingly important.
authors: National Institute of Environmental Health Sciences and National Institutes of Health, Research Triangle Park, NC 27709, USA. resnikd@niehs.nih.gov
authors: David B
authors: DB
authors: Resnik
authors: Sally S
authors: SS
authors: Tinkle
mesh_terms: D002986:Clinical Trials as Topic / Q000941:ethics*; D003257:Consumer Product Safety; D004353:Drug Evaluation, Preclinical / Q000941:ethics*; D050997:Nanomedicine / Q000941:ethics*; D014481:United States
references: Med Health Care Philos. 2007 Jun;10(2):173-84
references: 16944265
references: JAMA. 2000 May 24-31;283(20):2701-11
references: 10819955
references: Environ Health Perspect. 2005 Jul;113(7):823-39
references: 16002369
references: Nanomedicine (Lond). 2006 Aug;1(2):229-34
references: 17716112
references: Regul Toxicol Pharmacol. 1995 Feb;21(1):75-80; discussion 81-6
references: 7784639
references: Environ Health Perspect. 2005 Nov;113(11):1555-60
references: 16263511
references: JAMA. 2006 May 3;295(17):2072-5
references: 16670415
references: Environ Health Perspect. 1993 Oct;101(5):396-401
references: 8119247
references: Contemp Clin Trials. 2007 Jul;28(4):433-41
references: 17166777
references: J Nanobiotechnology. 2004 Dec 08;2(1):12
references: 15588280
references: N Engl J Med. 2004 Mar 11;350(11):1143-7
references: 15014189
references: J Pediatr. 2004 May;144(5):648-52
references: 15127004
references: Nanomedicine (Lond). 2006 Jun;1(1):9-12
references: 17716203
references: N Engl J Med. 2006 May 4;354(18):1869-71
references: 16672696
references: Nat Biotechnol. 2006 Oct;24(10):1211-7
references: 17033654
references: Sci Eng Ethics. 2005 Apr;11(2):187-201
references: 15915859
references: Dev World Bioeth. 2001 May;1(1):11-32
references: 12870505
references: Environ Health Perspect. 2003 Jul;111(9):1202-8
references: 12842774
references: Wake Forest Law Rev. 1999 Fall;34(3):671-714
references: 12664908
references: Nature. 2006 Nov 16;444(7117):267-9
references: 17108940
references: Curr Pharm Biotechnol. 2005 Feb;6(1):17-33
references: 15727553
references: Altern Lab Anim. 2006 May;34(2):225-39
references: 16704293
references: Health Care Anal. 2004 Jun;12(2):91-115
references: 15487813